Tim Whitten

Tim Whitten has extensive experience in the pharmaceutical industry, holding various leadership roles throughout their career. Tim currently serves as a Member of the Board of Directors at Astex Pharmaceuticals, Inc. since 2022. Prior to this, they were the CEO & President of TAIHO ONCOLOGY INC since April 2018 and also held the position of Chief Operating Officer from April 2017 to March 2018.

From 2013 to 2017, Whitten was the Chief Commercial Officer at Taiho Oncology, Inc., where they were responsible for building a commercial organization in the U.S. and assisting with the launch preparation in Europe of the company's first marketed product.

Before their time at Taiho Oncology, Whitten worked as an Experienced Biotech and Specialty Pharma Business Leader at Biotech and Specialty Pharma in 2012. Prior to that, they held the position of President & CEO at Insmed from December 2010 to September 2012.

Whitten has also served as President & CEO at Transave Inhalation Biotherapeutics, Inc. from June 2006 to January 2011. Earlier in their career, they worked at Pharmacyclics as SVP, Commercial Operations and Business Development from September 2001 to June 2006 and at Bristol-Myers Squibb as VP Global Marketing Oncology and Immunology from January 1999 to September 2001.

Tim Whitten attended West Virginia University from 1977 to 1980, where they obtained a Bachelor of Science (BS) degree in Pharmacy. Tim then pursued further education at the University of Virginia Darden School of Business, where they completed an MBA program. Additionally, Tim Whitten obtained a Master of Business Administration (MBA) degree from the University of Virginia Darden School of Business. Further details regarding the specific dates of enrollment or field of study during their MBA program are not provided.